Plain-English translation of NCT06237192 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new way to treat acute lymphoblastic leukemia (ALL) in adults by using chemotherapy in a more targeted way. Instead of using the same intense schedule for everyone, doctors will check for remaining cancer cells after the first phase of treatment and then decide whether to add blinatumomab (for B-cell ALL) or venetoclax (for T-cell ALL) to help eliminate them. The goal is to fight the cancer effectively while reducing unnecessary side effects.
Current ALL treatments use very intensive chemotherapy that can be hard on patients' bodies and cause serious side effects. This trial is exploring whether personalizing treatment based on whether cancer cells remain after the first round—and only adding extra targeted drugs when needed—can work just as well while being easier for patients to tolerate.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy over several months, starting with a week of steroid treatment followed by 8 weeks of induction chemotherapy. After that, doctors will test your blood to see if any leukemia cells remain; depending on the results, you may receive additional targeted treatment. You would then enter consolidation and maintenance phases lasting up to 2 years, with regular blood tests, bone marrow samples, and clinic visits to monitor your response and adjust treatment as needed.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Russia